{
    "clinical_study": {
        "@rank": "75464", 
        "arm_group": [
            {
                "arm_group_label": "Healthy controls", 
                "arm_group_type": "Active Comparator", 
                "description": "Healthy controls will be matched (age, gender, BMI) to monogenic diabetes subjects.  Healthy controls will participate in the following:\nOGTT\nIGI\nIGI with GLP-1 infusion\nOGTT with Exendin 9-39 infusion"
            }, 
            {
                "arm_group_label": "Monogenic diabetes", 
                "arm_group_type": "Experimental", 
                "description": "Monogenic diabetes subjects will be matched (age, gender, BMI) to healthy controls.  Monogenic diabetes subjects will participate in the following:\nOGTT\nIGI\nIGI with GLP-1 infusion\nOGTT with Exendin 9-39 infusion"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to explore the mechanisms of metabolic control in monogenic\n      diabetes patients treated with sulfonylurea medications."
        }, 
        "brief_title": "Incretin Regulation of Insulin Secretion in Monogenic Diabetes", 
        "completion_date": {
            "#text": "December 2020", 
            "@type": "Anticipated"
        }, 
        "condition": "Monogenic Diabetes", 
        "condition_browse": {
            "mesh_term": "Diabetes Mellitus"
        }, 
        "detailed_description": {
            "textblock": "Monogenic diabetes patients and healthy matched controls will be admitted to the University\n      of Chicago Clinical Resource Center for a total of 4 nights.  The following will take place\n      on separate days:\n\n        1. Oral Glucose Tolerance Test (OGTT): consume sugary drink and blood samples will be\n           collected at multiple time points\n\n        2. Isoglycemic glucose infusion (IGI) test: glucose will be infused via a vein in the arm\n           and and blood samples will be collected at multiple time points\n\n        3. OGTT during GLP-1 infusion\n\n        4. IGI during Exendin-9 infusion"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Monogenic Diabetes Subjects:\n\n        Inclusion Criteria:\n\n          -  Diagnosis of monogenic diabetes\n\n          -  Previously participated in US Neonatal Diabetes Registry (IRB 15617B) or Genetics of\n             diabetes mellitus (IRB 6858)\n\n          -  Age: 18 years +\n\n        Exclusion Criteria:\n\n          -  Pregnancy\n\n          -  Acute medical illness or chronic conditions including: cardiac failure, renal\n             insufficiency (estimated glomerular filtration rate <50 ml/min), hepatic\n             insufficiency (known cirrhosis or hepatitis), chronic obstructive pulmonary disease,\n             gastrointestinal disorders causing malabsorption, anemia (Hct < 36%), or uncontrolled\n             hypertension\n\n        Healthy Controls:\n\n        Inclusion Criteria:\n\n          -  Good general health\n\n          -  Stable weight for 6 months\n\n          -  Age: 18 years +\n\n        Exclusion Criteria:\n\n          -  Pregnancy\n\n          -  Acute medical illness or chronic conditions including: cardiac failure, renal\n             insufficiency (estimated glomerular filtration rate <50 ml/min), hepatic\n             insufficiency (known cirrhosis or hepatitis), chronic obstructive pulmonary disease,\n             gastrointestinal disorders causing malabsorption, anemia (Hct < 36%), or uncontrolled\n             hypertension"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "89 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 15, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01795144", 
            "org_study_id": "12-1517"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Healthy controls", 
                    "Monogenic diabetes"
                ], 
                "intervention_name": "GLP-1", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Healthy controls", 
                    "Monogenic diabetes"
                ], 
                "intervention_name": "Exendin 9-39", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Incretins"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "March 26, 2014", 
        "location": {
            "contact": {
                "last_name": "Siri A Greeley, MD, PHD", 
                "phone": "773-702-1000"
            }, 
            "facility": {
                "address": {
                    "city": "Chicago", 
                    "country": "United States", 
                    "state": "Illinois", 
                    "zip": "60637"
                }, 
                "name": "University of Chicago"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Incretin Regulation of Insulin Secretion in Monogenic Diabetes", 
        "overall_contact": {
            "email": "ndevine@peds.bsd.uchicago.edu", 
            "last_name": "Nancy Devine, RN", 
            "phone": "773-795-4417"
        }, 
        "overall_official": {
            "affiliation": "University of Chicago", 
            "last_name": "Siri Atma W Greeley, MD, PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2018", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Directly calculated from the difference between oral and IV stimulated insulin secretion", 
            "measure": "Incretin Effect", 
            "safety_issue": "No", 
            "time_frame": "Baseline"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01795144"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "University of Chicago", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Chicago", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}